Avoid common mistakes on your manuscript.
Correction to: Diabetes Ther (2021) 12:863–877 https://doi.org/10.1007/s13300-021-01014-0
The original article has been published with some errors.
The correct Table 2, Fig. 2, and Fig. 3 are given below.
In the results section of Abstract, there is correction in the sentence, the correct sentence is ‘‘HOMA-IR significantly decreased but HOMA-β was unchanged. FLI, ferritin, M2-BP, NAFLD fibrosis scores, and FIB-4 index significantly decreased whereas type IV collagen 7S domain did not significantly change’’.
In the Hepatic Function Biomarkers section of Results, the corrections in a sentence is ‘‘The NAFLD fibrosis score and FIB-4 index significantly decreased from baseline to weeks 12, 24 and 52 (Table 2). The type IV collagen 7S domain did not significantly change from baseline’’.
In the third paragraph of Discussion, the correct sentence is ‘‘Additionally, this study revealed improvement in the hepatic fibrosis biomarkers M2-BP, NAFLD fibrosis score, FIB-4 index, and ferritin following luseogliflozin administration in patients with T2DM complicated by hepatic dysfunction. However, type IV collagen 7S did not change significantly after luseogliflozin administration’’.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Seino, H. Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. Diabetes Ther 12, 2807–2811 (2021). https://doi.org/10.1007/s13300-021-01123-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-021-01123-w